共查询到20条相似文献,搜索用时 15 毫秒
1.
Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study 下载免费PDF全文
E. Guinard C. Bulai Livideanu H. Barthélémy M. Viguier Z. Reguiai M.A. Richard D. Jullien N. Beneton C. Bara P. Vabres A. Grandvuillemin M.C. Marguery F. Amelot M.P. Konstantinou H. Bagheri C. Paul the French Psoriasis Research Group 《Journal of the European Academy of Dermatology and Venereology》2016,30(8):1336-1341
2.
3.
4.
Ozawa A Ohkido M Haruki Y Kobayashi H Ohkawara A Ohno Y Inaba Y Ogawa H 《The Journal of dermatology》1999,26(3):141-149
This study analyzed data from treatments of 385 cases of generalized pustular psoriasis (GPP) from 325 hospitals in Japan. Retinoid treatment was effective in 84.1% of patients, methotrexate in 76.2%, cyclosporine in 71.2%, oral PUVA therapy in 45.7%, and tonsillectomy in 16.7%. Short-term therapy with systemic corticosteroid for GPP during only the phase with severe systemic clinical findings may be also effective (75.4%). However, these treatments for GPP each differed in clinical effects, prognosis, and side effects. These findings may be useful in creating guidelines for treatment of generalized pustular psoriasis. Further studies based on these specific clinical effects are necessary. 相似文献
5.
Erkan Alpsoy Mualla Polat Bilge FettahlıoGlu‐Karaman Ayse Serap Karadag Pelin Kartal‐Durmazlar Basak YalCın Selma Emre Didem Didar‐Balcı Asli Bilgic‐Temel Ercan Arca Rafet Koca Kamer Gunduz Murat Borlu Tulin Ergun Seval Dogruk‐Kacar Ayca Cordan‐Yazici Pınar Dursun Ozlem BilgiC Serap Gunes‐Bilgili Neslihan Sendur Ozge Baysal Ibrahim Halil‐Yavuz Gizem Yagcioglu Ertan Yilmaz Ufuk Kavuzlu Yesim Senol 《The Journal of dermatology》2017,44(8):885-891
Internalized stigma is the adoption of negative attitudes and stereotypes of the society regarding a person's illness. It causes decreased self‐esteem and life‐satisfaction, increased depression and suicidality, and difficulty in coping with the illness. The primary aim of this study was to investigate the internalized stigma state of psoriatic patients and to identify the factors influencing internalized stigma. The secondary aim was to identify the correlation of internalized stigma with quality of life and perceived health status. This multicentre, cross‐sectional study comprised 1485 patients. There was a significant positive correlation between mean values of Psoriasis Internalized Stigma Scale (PISS) and Psoriasis Area and Severity Index, Body Surface Area, Dermatological Life Quality Index and General Health Questionnaire‐12 (P < 0.001 in all). Lower percieved health score (P = 0.001), early onset psoriasis (P = 0.016), family history of psoriasis (P = 0.0034), being illiterate (P < 0.001) and lower income level (P < 0.001) were determinants of high PISS scores. Mean PISS values were higher in erythrodermic and generalized pustular psoriasis. Involvement of scalp, face, hand, genitalia and finger nails as well as arthropathic and inverse psoriasis were also related to significantly higher PISS scores (P = 0.001). Our findings imply that psoriatic patients experience high levels of internalized stigma which are associated with psoriasis severity, involvement of visible body parts, genital area, folds or joints, poorer quality of life, negative perceptions of general health and psychological illnesses. Therefore, internalized stigma may be one of the major factors responsible from psychosocial burden of the disease. 相似文献
6.
Ozden MG Tekin NS Gürer MA Akdemir D Doğramacı C Utaş S Akman A Evans SE Bahadır S Oztürkcan S Ikizoğlu G Sendur N Köse O Bek Y Yaylı S Cantürk T Turanl AY 《Pediatric dermatology》2011,28(3):306-312
To analyze the effect of possible risk factors, including breastfeeding, on the development of childhood-onset psoriasis, a multicenter case-control study with prospective collection of data was performed. Using a standard questionnaire, personal and specific variables including family history of psoriasis, maternal and environmental tobacco smoke exposure, body mass index (BMI), exclusive and partial breastfeeding for at least 3 and 12 months, cow's milk intake before 1 year, birth delivery method, and stressful life events were collected during 2009 from 537 patients with psoriasis and 511 controls younger than 18. Overall, patients more frequently reported exposure to environmental tobacco smoke at home and stressful life events in the year preceding the diagnosis than controls. The odds ratios (OR) for smoking and stressful life events were 2.90 (95% confidence interval [CI]=2.27-3.78) and 2.94 (95% CI=2.28-3.79), respectively. In addition, children with psoriasis were more likely to have a higher BMI (>26) than controls (OR=2.52; 95% CI=1.42-4.49). High BMI, environmental tobacco smoke exposure at home, and stressful life events may influence the development of pediatric psoriasis. 相似文献
7.
Ginarte M 《Journal of the American Academy of Dermatology》2011,64(6):1184; author reply 1184-1184; author reply 1185
8.
9.
Safety and efficacy of biological therapies in patients with psoriasis with alcoholic cirrhosis: a French retrospective study of 23 cases 下载免费PDF全文
E. Begon N. Beneton C. Poiraud C. Droitcourt C. Jacobzone A. Vermersch‐Langlin V. Descamps J.L. Perrot A. Khemis V. Pallure A.C. Fougerousse M. Sigal‐Grinberg J.‐L. Schmutz C. Goujon Z. Reguiai Groupe d'Etudes Multicentrique GEM RESOPSO 《The British journal of dermatology》2018,179(2):512-513
10.
Saadia Tabassum MBBS FCPS Atiya Rahman MBBS FCPS Safia Awan MSc Kausar Jabeen MBBS FCPS Joveria Farooqi MBBS FCPS Bilal Ahmed MSc Sadia Masood MBBS FCPS Manzor Memon MCPS Ajmal Rashid MBBS FCPS Muhammad R. Soomro MBBS FCPS Azam J. Samdani MBBS PhD Shaheen Naveed MBBS FCPS Naseema Kapadia MBBS FCPS 《International journal of dermatology》2019,58(6):672-678
11.
Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study 下载免费PDF全文
J. F. Schwensen A. Clemmensen C. Sand R. Gniadecki L. Skov C. Zachariae L. Iversen M. Rasmussen S. F. Thomsen 《Dermatologic therapy》2017,30(6)
Secukinumab (anti‐IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real‐life data on effectiveness and safety lack. We aimed to present real‐life data of all Danish patients treated with secukinumab (n = 69). At baseline, before initiation of treatment with secukinumab 300 mg (47.8%) or off‐label treatment with secukinumab 150 mg (52.2%), the median PASI score was 7.1. A total of 66.7% (34/51) and 52.9% (27/51) of patients still on secukinumab at week 12 achieved a PASI (Psoriasis Area and Severity Index)‐50 and PASI‐75 of 66.7% and 52.9%, respectively. A total of 83.0% (44/53) and 60.4% (32/53) of the patients had a PASI‐score < 5 and PASI‐score < 2, respectively, after 12 weeks on treatment with secukinumab. A third of the patients had secukinumab discontinued due to limited clinical improvement or adverse events (n = 23) within a median of 92 days (interquartile range 51–212 days). Notably, the majority of the patients may represent a particularly difficult‐to‐treat group of patients, as 92.8% had been refractory to other biologic treatment. A total of 26.1% (n = 18) experienced adverse events. Secukinumab appears to be an effective treatment option with a favorable side effect profile in patients with plaque psoriasis who are refractory to or have side effects of traditional biologic drugs. 相似文献
12.
E Christophers U Mrowietz H H Henneicke L F?rber D Welzel 《Journal of the American Academy of Dermatology》1992,26(1):86-90
Interim results of a randomized, controlled, dose-finding study conducted in 24 dermatology centers on 217 patients with severe chronic plaque psoriasis (entry psoriasis area and severity index of at least 15) are presented. Patients were first treated with cyclosporine either 1.25 or 2.5 mg/kg/day (Sandimmune); in case of inadequate response the dosage was increased to a maximum of 5 mg/kg/day. Cyclosporine was given for 12 to 36 weeks. Treatment was classified as "successful" if the psoriasis area and severity index was reduced to 25% or less of the baseline value or below 8. At the end of the treatment period 18% of patients had improved their psoriasis area and severity index "successfully" with the initial dose of 1.25 mg/kg/day. "Successful" improvement with the initial dose of 2.5 mg/kg/day was achieved in 56% of the cases. In the 1.25 mg group, 44 patients had to increase their dose to 2.5 mg/kg/day and 31 patients to 5 mg/kg/day. In 29 patients whose dosages were started at 2.5 mg/kg/day the dosage was subsequently increased to 5 mg/kg/day. Although 1.25 mg/kg/day proved to be effective in some cases, 2.5 mg/kg/day of cyclosporine is the optimal starting dose. Adverse events were observed in 10% of the patients taking 1.25 mg/kg/day, in 20% taking 2.5 mg/kg/day, and in 32% taking 5 mg/kg/day. The most common were gastrointestinal complaints, followed by the common cold and other viral infections. An increase of serum creatinine level above 130 mumols/L occurred in five patients who could continue therapy after reducing the dose.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
13.
14.
15.
《Annales de dermatologie et de vénéréologie》2022,149(3):165-168
ObjectiveMycoplasma genitalium (MG) infection accounts for 10–35% of non-gonococcal non-chlamydial (NGNC) urethritis. However, given that most people infected with MG do not develop symptoms and that antimicrobial resistance is increasing worldwide, there is no evidence of any benefits of screening asymptomatic individuals. We conducted this study to describe MG screening practices and outcomes at a French Sexually Transmitted Infections (STI) center in which MG testing was performed selectively and multiplex assays were not carried out [i.e., simultaneous screening for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and MG].MethodsA retrospective, observational, single-center study was conducted at the STI unit of Saint-Louis Hospital in Paris. The records of all patients undergoing MG testing from January 1st, 2017, to December 31st, 2018, were reviewed. The primary aim of the study was to describe and evaluate the proportion of MG-positive (MG+) patients among those tested. Secondary objectives were determination of the prevalence of MG+ status among symptomatic patients, risk factors associated with MG infection, and therapeutic modalities and efficacy.ResultsTwo hundred and forty-nine patients underwent MG testing, 28 (11%) of whom were positive (MG+). The prevalence of MG+ status among symptomatic NGNC patients was 12%. HIV-positive (HIV+) status was significantly associated with MG+ status in univariate and multivariate analyses (Odds Ratio = 7.3, 95% Confidence Interval 1.3-41.7; P = 0.02). Twenty-three patients (85%) received antibiotics. Eighteen (67%) received azithromycin for 5 days, but 7 had clinical resistance. No quinolone resistance was reported.ConclusionDespite unavailability of multiplex testing at our facility, which led to targeted-only screening for MG, its relatively high local prevalence is in keeping with what is generally observed at similar facilities across the world, where use of multiplex tests enables systematic screening for MG alongside NG and CT. This reinforces the current recommendations in Europe, France and the US against systematic MG testing or treatment in asymptomatic patients. 相似文献
16.
Sohn S Schoeffski O Prinz J Reich K Schubert E Waldorf K Augustin M 《Dermatology (Basel, Switzerland)》2006,212(2):137-144
BACKGROUND: There is little information concerning the costs of psoriasis and patients' quality of life (QoL) in Germany. OBJECTIVE: To obtain data on the annual costs and QoL(to follow in a further publication) of patients with moderate to severe plaque psoriasis. METHODS: Between October 2003 and February 2004, six office-based dermatologists and eight dermatology outpatient departments retrospectively documented cost-of-illness data from a societal cost perspective in 184 patients over a 12-month period. Patients were stratified into three subgroups according to their treatment scheme. RESULTS: Mean total costs amounted to euro 6,709 per patient and year. The mean PASI score was 18.2 and PBSA 28.9%. Annual costs were highest with euro 8,831 in high-need patients. They also showed the highest PASI score (22.2). CONCLUSION: Moderate to severe plaque psoriasis is associated with tremendous costs, particularly in patients not adequately controlled by conventional therapies, while the outcomes of patients were unsatisfactory. 相似文献
17.
L. Charbit E. Mahé A. Phan C. Chiaverini F. Boralevi E. Bourrat A. Lasek A. Maruani F. Aubin C. Droitcourt S. Barbarot S. Mallet J. Mazereeuw‐Hautier E. Begon C. Abasq P. Plantin A.‐L. Souillet S. Hadj‐Rabia A.‐C. Bursztejn the Groupe de Recherche de la Société Française de Dermatologie Pédiatrique 《The British journal of dermatology》2016,174(5):1118-1121
18.
19.
20.
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study 下载免费PDF全文
M. Esposito P. Gisondi A. Conti A. Giunta M. del Giglio M. Di Mercurio L. Veneziano G. Ferrucci L. Bianchi S. Chimenti G. Girolomoni 《Journal of the European Academy of Dermatology and Venereology》2017,31(5):863-869